Suchergebnisse - "Hwu, Wen-Jen"

PubPharm (20)

1

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma : KEYNOTE-029 Part 1B

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Carlino, M. | Menzies, A. | Atkinson, V. | +16

2

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

enthalten in: Nature medicine | 2018

von Amaria, R. | Reddy, S. | Tawbi, H. | +42

ErratumIn: Nat Med. 2018 Oct 25;:. - PMID 30361510

3

Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern

enthalten in: Journal of cutaneous pathology | 2018

von Trinidad, C. | Nelson, K. | Glitza Oliva, I. | +8

4

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma : Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Atkins, M. | Hodi, F. | Thompson, J. | +14

CommentIn: Ann Transl Med. 2019 Jul;7(Suppl 3):S95. - PMID 31576303

5

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

enthalten in: Cancer immunology, immunotherapy : CII | 2017

von Patel, S. | Kim, D. | Bassett, R. | +8

6

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029) : an open-label, phase 1b trial

enthalten in: The Lancet. Oncology | 2017

von Long, G. | Atkinson, V. | Cebon, J. | +21

CommentIn: Lancet Oncol. 2017 Sep;18(9):1144-1145. - PMID 28729152

7

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

enthalten in: Cancer immunology immunotherapy | 2017

von Patel, S. | Kim, D. | Bassett, R. | +8

8

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

enthalten in: Cancer immunology immunotherapy | 2017

von Patel, S. | Kim, D. | Bassett, R. | +8

9

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

enthalten in: Cancer immunology immunotherapy | 2017

von Patel, S. | Kim, D. | Bassett, R. | +8

10

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

enthalten in: Journal of cutaneous pathology | 2017

von Curry, J. | Tetzlaff, M. | Nagarajan, P. | +9